Clinical Trial Update: Safety And Efficacy Of Ziprasidone In Children And Adolescents With Bipolar I Disorder (Manic Or Mixed) (Protocol A1281196) [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating ziprasidone for bipolar I disorder in children and adolescents has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Disorder

Drugs mentioned

• Ziprasidone (ziprasidone)

Snippet

Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Conditions: Bipolar Disorder | Phase 3 | Status: WITHDRAWN